Meeting
2017 Gastrointestinal Cancers Symposium
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers.
Authors
Filip Janku
Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX
Filip Janku , Afsaneh Barzi , Andrea Sartore-Bianchi , Takeo Fujii , Andrea Cassingena , Giulia Siravegna , Daniel D. Karp , Sarina Anne Piha-Paul , Vivek Subbiah , Apostolia Maria Tsimberidou , Helen J. Huang , Silvio Veronese , Federica Di Nicolantonio , Mark G. Erlander , Rajyalakshmi Luthra , Scott Kopetz , Funda Meric-Bernstam , Salvatore Siena , Heinz-Josef Lenz , Alberto Bardelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 602)
DOI
10.1200/JCO.2017.35.4_suppl.602
Abstract #
602
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.
First Author: Filip Janku
Poster
2015 Gastrointestinal Cancers Symposium
Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations.
First Author: Jason C. Poole
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
First Author: Khalid Jazieh
Poster
2022 ASCO Annual Meeting
Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.
First Author: Bennett Adam Caughey